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Abstract
This thesis examines the chemistry of 1-benzazepines and the possibility of alkylation by
electrophilic addition. Due to the lack of previous research on this subject, there is a great deal
of work that can be done to explore the reactivity of these compounds. It has recently been
suggested that 1-benzazepines are intermediates in the synthesis of prospective analogues of βchemokine receptor CCR5 antagonists for treatment of HIV/AIDS. The method for producing
these treatment drugs, however, is not very effective or efficient. A new process proposed by my
mentor is a more direct synthesis of CCR5 antagonists and the information presented in this
thesis lays the groundwork for this method. The goal in the following experiments was to find a
way to add alkyl and other groups to C3 of the benzazepine after generating a benzazepine anion.
The success of this work would allow for greater variation in the later preparation of analogues
of CCR5 antagonists. The synthesis methods we used generated an anion at a low temperature
of -65°C. Four different electrophiles were successfully added to the benzazepine using our
reaction methods. The expected deprotonation and addition site was C3, due to the previously
established stability of the 3H-1-benzazepine.

The first attempt with deuterium as an

electrophile provided hopeful results, as it was present in significant levels at C3 after the
addition. A methyl group added only at C3 of the benzazepine, while a benzyl group seemed to
attach at the nitrogen atom, and at both C3 and C5. p-Anisaldehyde gave the product of the
reaction at either C3 or C5, as either 3- or 5-methoxy-benzyl alcohol. An additional finding was
the ability of the methyl group to lock in the conformation of the molecule, since this did not
occur with the unsubstituted 3H-1-benzazepine.
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Background
HIV, human immunodeficiency virus, is estimated to affect 56,300 Americans each year
with new infections.[1] Although this number has been seemingly stable over the years, it is still
a devastating fact of life. As a retrovirus, HIV causes the slow deterioration of an individual’s
immune system by destroying CD4+ T cells, which are involved in fighting diseases in the
body.[1] These cells are essentially the means by which HIV spreads, as it replicates within them.
In most untreated cases, 10-15 years after becoming infected with HIV, the virus develops into
AIDS.[2] With the advent of antiretroviral drugs, however, this transformation has been slowing
down.
Antiretroviral drugs are medications used as a form of treatment for HIV.[2] When
several of them are used in combination with each other, the method is called highly active
antiretroviral treatment or HAART.[3] HAART works by inhibiting certain steps of the HIV
replication process, which leads to a reduction of HIV in the blood.[3] Due to the fast replication
of T cells, however, HIV often mutates and forms a resistance to treatment drugs. The basis for
HAART is that the treatment is strength in numbers, with a mixture of 3 or 4 drugs working
together to lower HIV levels.[3] HAART has been successful in reducing the reproducing power
of HIV, but it has yet to wipe out the virus completely. There are other issues with the drugs
used in HAART in that they can be quite toxic and harmful. Therefore, it is clearly of extreme
importance that research continues developing a more effective and efficient drug to fight HIV.
HIV has a specific process by which it invades cells and begins to reproduce more virus
particles. A component that is extremely critical to the success of the HIV particle fusing with a
cell is the CCR5 co-receptor, a beta chemokine receptor.[4] CCR5 is a protein found on T cells
that facilitates HIV infection and serves as a means for HIV to enter T cells. Fusion between the
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viral envelope and the CD4+ cell membrane can only occur when the HIV particle is bound to
both CD4 and this co-receptor. CCR5 also plays a key role in how HIV can progress into
AIDS.[5] More important than the CCR5 co-receptor’s role in HIV infection, however, is its
function as a drug target.
Research of the CCR5 co-receptor has actually encountered a type of mutation, called the
CCR5-Delta32 mutation.[5] This is a mutation in the CCR5 gene, which doesn’t produce a
functional protein. A person that is homozygous for CCR5-Delta32 has almost complete
protection against HIV-1 infection. A heterozygous individual also shows some resistance to
HIV infection. Therefore, a further study of CCR5 is essential because individuals with mutated
receptors are still normal, while resisting infection to some degree. This thesis focuses on laying
the groundwork for potential synthesis of related analogues of CCR5 antagonists that may cause
this same effect of HIV resistance.
The specific work of this thesis involves the generation of alkylated-1-benzazepines,
which are potential intermediates in the synthesis of the CCR5 antagonist and analogues. These
1-benzazepines have not been thoroughly studied, but their role in this process has significant
potential. The results of this project prove that 1-benzazepines will successfully react to create a
variety of derivatives of the molecule, which could lead to further advances in CCR5 antagonists.
The data and experimental methods within this thesis provide the initial work necessary for this
future goal.
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Introduction
A significant component necessary for HIV replication is the β-chemokine co-receptor
CCR5.[4] Previous research has demonstrated that individuals with a non-functional receptor,
due to a mutation of the gene, are resistant to strains of HIV-1 infection.[6-9] Studies of a CCR5
antagonist in treatment drugs are currently underway. The 1-benzazepine core (highlighted in
red, 1) is a structural feature in a series of β-chemokine receptor CCR5 antagonists.[6-9]
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O
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The synthetic route to this molecule is plagued by low yields in several of the steps.[6-9] If a new
and more efficient method could be determined to synthesize this compound to directly target the
virus and cause less damage to the body, this could make a significant medical impact.
Dr. Keith Ramig and Dr. Edyta Greer have proposed an improved synthesis of this
molecule (Scheme 1)
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In order for this synthesis to be implemented in the future, much background work will have to
be carried out to probe new chemistry that these 1-benzazepines might undergo. The hope is not
only to be able to prepare the drug molecule above, but also analogues with closely related
structures. It is possible that one of these analogues could have more beneficial properties than 1
itself. The chemistry of 3H-1-benzazepines such as 5 has not been well studied in the literature,
so considerable research will have to be performed to probe the reactivity and usefulness of these
compounds as possible intermediates in the synthesis of the CCR5 antagonist and analogues.
In one of the few studies that has been carried out recently, Ramig et al. were able to
prepare a variety of 1-benzazepines by a novel method, to be discussed more in detail
below.[10,11] One of the study’s shortcomings was its inability to produce benzazepines that have
anything but hydrogen atoms at C3. This would not allow versatility in the eventual preparation
of analogues of antagonist 1. The goal of my thesis is to redress this shortcoming by finding a
way to place substituents such as alkyl groups at C3 of the benzazepines, after the benzazepine
core has already been prepared (Scheme 2).
Scheme 2
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We propose that a benzazepine anion should be obtainable from a benzazepine by treatment with
a strong base such as lithium diisopropylamide (LDA), and that the anion should react with

8
compounds such as alkyl halides and aldehydes to give a new benzazepine with either an alkyl
group or an α-hydroxyalkyl group at C3. These kinds of alkyl groups are the most commonly
used type of varied substituents when evaluating the pharmacology of a series of prospective
drug molecules.
Our research is based on the method used by Ramig et al. involving 2-fluoroaniline 10
and an aryl vinyl ketone 11 (Scheme 3).[10,11] The reaction was a single flask procedure that
produced 1-benzazepines in useful yields. With this procedure, they created benzazepines with
different substituents through the use of appropriately substituted aryl vinyl ketones. These gave
3H-1-benzazepines 12 with varying groups on C2, C4, and C5. Initially the 5H-1-benzazepine
13 seemed to form, but this rearranged to give the 3H-1-benzazepine 12, which was more stable.
As discussed previously, the synthesis failed when attempts were made to place an alkyl group at
C3 by employing the corresponding aryl vinyl ketone.
Scheme 3

Additionally, only a few others have contributed to the research on benzazepines.
Scheme 3 (shown above) was based on the results of Brooke and Matthews,[12] who observed
this mechanism first. They used aromatic amines, in which all the carbons were fluorinated, and
acetophenone to generate very low yields of benzazepines.[12] Singh and Batra demonstrated the
synthesis of substituted 1H and 3H-1-benzazepines using SnCl2 reduction of nitro groups on
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alkanoates.[13] When they varied the groups at C2 and C4 of the benzazepine, they observed that
the substituents affected which isomer formed. Similarly, Kharraz et al. explored other areas of
benzazepine synthesis. They successfully examined the possible rearrangements of the 1H to the
5H-1-benzazepine and the 5H to the 3H-1-benzazepine.[14,15] In one study, 5H-1-benzazepines
14 were rearranged to the 3H-1-benzazepines 16. In a different study, 3H-1-benzazepines 16
were prepared by two synthetic pathways: the chemical oxidation of the 2,5- and 2,3-dihydro1H-1-benzazepines and the rearrangement of the 5H-1-benzazepines 14.[15] The yields in these
two studies were less than 46% and 36% respectively, which were too low to be useful.
Scheme 4

The fact that the 5H-1-benzazepine isomerizes to the 3H-1-benzazepine with the help of a strong
base (Scheme 4) is significant because it implies deprotonation. This is relevant to the main
focus of this thesis because a benzazepine anion was generated by deprotonation and then
alkylated, as in Scheme 2 above. The isomerization also supports the finding that the 3H-1benzazepine is the most stable.
The benzazepine molecules can be examined with the help of azepine studies as well.
Streef’s research on azepines, which are simpler cousins of benzazepines, proves to be very
valuable to us, and has given research on benzazepines a new direction in which to grow.[16] The
study examined the possibility of adding electrophiles to azepines.

Streef was able to

deprotonate the 2-diethylamino-5-phenyl-3H-azepine 17 in a solution of 1,2-dimethoxyethane by
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LDA, in ether under nitrogen and at room temperature, to generate an azepine anion 18.[16] After
this, the introduction of an alkyl halide or other electrophiles was successful in adding a new
group to the ring at C3 (Scheme 5).
Scheme 5
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These electrophiles E included D2O with a 75% yield, methyl iodide, dimethyl disulfide,
and benzyl bromide all with 60-65% yields.[16] The results of this reaction demonstrated that
azepines could be deprotonated by LDA and then alkylated at C3. It is apparent that substitution
at carbon three is still the most stable form of the molecule, as no alkylation was seen at the other
possible sites of C5 and N1. The promising data from this experiment paved the way for a
similar study using benzazepines. Only a few various groups were used in the reaction and
actually added to the ring, but the success of the experiment gave us basis on which to build.
With this research as a guideline, we prepared a similar reaction for our benzazepine and
achieved interesting results of our own.
We have been successful in generating a benzazepine anion 8 (Scheme 2), which
involved removing a proton from the ring to leave it negatively charged. With the negative
charge, the positively charged electrophile became attracted to the ring and reacted with it. In
this way, a new carbon-carbon bond was formed. The next step was ascertaining where the
electrophiles ended up on the ring, after reacting with the anion. There was the possibility that
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they would end up on the nitrogen atom, at C3, or at C5. As we already established the 3H-1benzazepine as the most stable form, we were able to see how these additions ended up affecting
the stability of the molecule. More importantly, the successful synthesis of these 1-benzazepines
proved that it might be possible to generate CCR5 antagonist analogues more efficiently.

Results and Discussion
Synthesis of deuterated benzazepine 9A
Initially, the reactions of the benzazepine anion 8 and various alkyl groups were designed
following the results of Streef,[16] but had to be modified and adapted as the experiments
proceeded. The first reaction with D2O was attempted at room temperature, then at 0°C, and
finally at -65°C. Initially excess LDA was used as demonstrated by Streef’s results. We
believed it was necessary in order to fully deprotonate the benzazepine and force the reaction to
the right, rather than remain in equilibrium. However, as shown by the results we found that this
was not required. The first reaction at room temperature and with excess LDA gave a 30% yield
of 3D-1-benzazepine. The following D2O experiments were changed to be a 1:1 molar ratio of
benzazepine and LDA. As we attempted this, however, we found that the reaction was occurring
similar to a titration. The LDA was not immediately deprotonating the benzazepine after the first
drop, and it actually took a varying amount to generate the anion. Essentially, the color change
to dark green (presumably the color of the benzazepine anion) had to occur first and then the 1
equivalent of LDA was added. In the second reaction, the NMR analysis of the crude reaction
mixture showed the characteristic CH2 peak of the benzazepine, but with an integration value of
1. This meant that it was representing only one hydrogen and that the other had been replaced by
a deuterium. After recrystallization, however, NMR showed mainly 3H-1-benzazepine 7. Thus
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the purified compound had either regained the protium during purification, or the analysis of the
crude mixture was faulty.
The next D2O reaction occurred at 0°C but again, NMR analysis determined that only
20% of the 3H had been replaced by a deuterium. One reason for the low yield could be that the
plate during chromatography acted as an acid, replacing some of the deuterium with protium.
Additionally, the 3D-1-benzazepine 9A present was in equilibrium with 5D-1-benzazepine
making it difficult for peak integration measurement. The last reaction attempted with D2O was
performed at -65°C and NMR showed the presence of 15% 3D-1-benzazepine 9A. It was
determined that -65°C was the optimal temperature for the reaction because at low temperatures
there were fewer by-products.
Four attempts were made to achieve a significant level of deuterium incorporation. The
highest level of deuterium seen across all the experiments was about 30%. We found later, by
control experiments, that deuterium was being lost during the required chromatographic
purification. But the fact that any deuterium was seen was a good indication that the proposed
anion was being formed.

Synthesis of methylated benzazepine 9B
Methyl iodide was the second electrophile attempted in this experiment. During the first
trial, NMR of the crude sample immediately demonstrated some success. There was a quartet
around 2.6 ppm, which was the hydrogen at C3, and a doublet at around 1.0 ppm representing
the CH3 group in 3-methyl-1-benzazepine 9B. Interestingly, it was also discovered that the
molecule was not undergoing a fast conformational change. Normally with the unsubstituted
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3H-1-benzazepine 7, the NMR spectrum shows that the non-planar azepine ring is undergoing a
conformational change (i.e. ring-flipping) in solution at a relatively fast rate. However, the
methyl group at C3 on the benzazepine 9B seems to lock the molecule into one conformation. It
was thought that by lowering the temperature, the peak would sharpen as the transformation
would have slowed down, but this wasn’t the case. It was then thought that heat would make the
peak broader, but this was also not the case. Therefore, the conformational change was not
occurring.

Radial chromatography using 2.5% EtOAc/hexane gave a mixed fraction of 3-

methyl-1-benzazepine 9B and 3H-1-benzazepine 7. A second radial chromatography using 1%
EtOAc/hexane provided a good separation. NMR showed the 3-methyl-1-benzazepine 9B with
very slight impurities and recrystallization using hexane produced yellow crystals with a melting
point of 109-111°C.
Another trial of the methylation reaction produced better results when the reaction time
was extended. After the addition of LDA, an hour was allowed to elapse before adding methyl
iodide and after adding it, another hour was allowed to pass. The crude oil of this reaction
became a solid at room temperature. Radial chromatography using 1% EtOAc/hexane gave a 3methyl-1-benzazepine 9B sample that was 96.5% pure and the melting point was 106-107°C.
After two recrystallizations with hexane, large yellow crystals formed with a melting point
between 109-111°C. All of the crystals combined gave a 43% recovery rate for the reaction.
The last reaction with methyl iodide was scaled up to create a greater amount of product.
Additionally, the crude mixture was washed twice with water and ether for a better yield. NMR
of this crude sample showed barely any 3H-1-benzazepine 7, with the majority of the product
being 3-methyl-1-benzazepine 9B. After radial chromatography, NMR of the product showed
only 4.5% 3H-1-benzazepine and mainly 3-methyl-1-benzazepine 9B. The 30% yield for this
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reaction was the best yield produced for the methylation reaction. X-ray analysis of crystals
confirmed that the methyl group was attached to the benzazepine at C3 and that it was locked
into a specific conformation (see ORTEP Diagram).

ORTEP Diagram of 9B

Synthesis of benzylated benzazepine 9C
The third electrophile attempted was benzyl bromide, which proved to give complicated
results. The initial TLC (10% EtOAc/hexane) of the crude sample showed the 3H-1-benzazepine
7 spot as well as another spot above it, believed to be 3-benzyl-1-benzazepine 9C, with a
significant amount of space between them. Proton NMR showed as expected the benzazepine
starting material, plus two compounds with the spectral characteristics predicted for a benzylated
benzazepine, a downfield doublet (CH next to CH2) and an upfield doublet (CH2). This is
consistent with benzylation having occurred at both C3 and C5. If benzylation occurs at C5,
compound 20 is produced.
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The first radial chromatography produced 2 fractions: fraction 1 contained a benzylated isomer
and an unknown, fraction 2 contained 3H-1-benzazepine 7 and the other benzylated isomer.
Preliminary NMR data shows that the unknown in fraction 1 is most likely the 1-benzyl-1benzazepine 21. Recrystallization of both fractions from ethyl acetate/hexane helped to further
isolate and separate the components. Fraction 1 crystals were of the 1-benzyl isomer with a
sharp melting point of 131-133°C. Although the proton NMR revealed the structure 21, the
compound was submitted for X-ray analysis to prove this. The filtrate contained an inseparable
mixture (see list of TLC solvents used below) of the 1-benzyl-1-benzazepine, and either the 3benzyl-1-benzazepine or 5-benzyl-1-benzazepine isomer. Fraction 2 crystals were the 3H-1benzazepine 7 and fraction 2 filtrate was a mix of 7 and the other benzylated isomer.
Radial chromatography required these TLC eluents be tested on both fractions above:
30% CH2Cl2/hexane, 2% isopropyl alcohol/hexane, 1% isopropyl alcohol/hexane, 10%
Et2O/hexane, 100% benzene, 100% toluene, 50% toluene/hexane, 25% benzene/hexane, 50%
benzene/hexane, and 75% benzene/hexane. 100% Benzene for fraction 2 crystals and filtrate
was the only solvent that showed a good separation; however, 50% and 25% were less polar and
the spots didn’t move as fast so a compromise was chosen for radial chromatography. 40%
Benzene/hexane eluent was first chosen for radial chromatography because the spots needed to
separate at a good rate. A sample of one of the benzylated isomers was produced in about 95%
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purity. Another attempt using 50% benzene/hexane gave a sample of about 99% purity. After
recrystallization from ethyl acetate/hexane, the compound was in the form of light yellow
needles and had a melting point of 123-124°C.

This has been submitted for X-ray

crystallography analysis.
The NMR spectra of both fractions were used to calculate the percent yield of all four
compounds in the original crude sample. The peak locations and integration values were utilized
to form a ratio between the crystals and filtrates of each fraction, which allowed us to come up
with the percent and thereby, mass of each component. Fraction one consisted of 79% 1-benzyl1-benzazepine and 21% of either 3-benzyl-1-benzazepine 9C or 5-benzyl-1-benzazepine 20. A
comparison to the theoretical yields of these compounds then enabled us to determine that there
was 35% yield of 1-benzyl-1-benzazepine 21 and 9% yield of either of the other isomers (i.e. 9C
or 20) out of the total original sample. Fraction two contained 42% of the 3H-1-benzazepine 7
starting material and 58% of either 3-benzyl-1-benzazepine 9C or 5-benzyl-1-benzazepine 20.
Again using the theoretical yields, it was calculated that there was a 23% recovery of 3H-1benzazpine, the starting material, and a 43% yield of one of the 3- or 5-benzylated isomers in the
crude mixture. Together these yields add up to a theoretically impossible value of 110% (35%,
9%, 23%, 43%), which may be an indication that there are other compounds present that we
don’t know about. Despite this, the overall reaction generated a significant amount of new
products, and showed that in contrast to methyl iodide, which gave only one of the three possible
alkylated isomers, benzyl bromide gave all three. The reasons for this are at present a mystery,
but are under investigation.
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Synthesis of α-hydroxy alcohol benzazepine 9D
The final electrophile attempted in this experiment was p-methoxybenzaldehyde also
known as p-anisaldehyde. A TLC (10% EtOAc/hexane) of the crude product, as well as of the
workup mixture later, showed that there were two products to isolate. The NMR spectra of the
crude sample showed the presence of anisaldehyde with a singlet peak at 10 ppm and a peak at 4
ppm, representing a methoxy group. Although we are unsure whether the p-methoxybenzyl
alcohol added to C3 or C5, either way a new chiral center was created. This can cause analysis
of the product to be complicated.
Radial chromatography led to the isolation of two new compounds. NMR analysis of
compound one showed a methoxy group, an alcohol, and aromatics that confirmed the presence
of desired 3-methoxy-benzyl alcohol 9D or 5-methoxy-benzyl alcohol 22.

N

Ph

Ph

HO
H

OCH3
22
Compound two proved to be difficult to dissolve for NMR analysis. It was separated into two
NMR samples: sample one with methanol-d, DMSO-d6, and acetic acid-d4 as solvents; and
sample two with solely acetic acid-d4 as a solvent. Sample one did not give a solution, so it was
dissolved in CH2Cl2, and washed with 10 mL of NaHCO3 and 10 mL of water. The CH2Cl2 layer
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was isolated and under reduced pressure gave a yellow film. This was recrystallized from ethyl
acetate/hexane. NMR analysis of the crystals showed similarities to compound one. Both
spectra have three peaks between 3.6 ppm and 5 ppm with equal integration values. The
difference, however, is in the chemical shifts of the peaks in each of the spectra. We suspect that
compound one and compound two crystals are the 3- and 5-methoxy-benzyl alcohol isomers 9D
and 22, but at this point it is impossible to say which is which.
NMR sample two, of compound two, showed the presence of anisaldehyde and two
unknowns. One of these may be either 9D or 22. After it was left overnight in the acidic NMR
solvent, we found that one of the unknown compounds (9D or 22) had started to convert back to
anisaldehyde.

After three days, another NMR showed an increase in the amount of

anisaldehyde. This sample was then washed with 10 mL of NaHCO3 and 10 mL of CH2Cl2, and
the CH2Cl2 layer was isolated under reduced pressure. This was also recrystallized from ethyl
acetate/hexane. A further analysis by TLC and NMR showed that the 3H-1-benzazepine starting
material may be present in addition to anisaldehyde, however, this could not be confirmed. At
this point, there remains one unknown compound to be purified and identified.
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Experimental
Deprotonation and Alkylation of the 3H-1-benzazepine 7
Synthesis of deuterated benzazepine 9A
Scheme 6
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General Method: The reaction occurred at three different temperatures: room temperature, 0°C,
and -65°C. To a flame-dried 3-neck reaction flask under nitrogen was added 1 mmol (295 mg)
of 3H-1-benzazepine 7. This was followed by 10.0 mL of anhydrous THF. A 1:1 mole ratio of
LDA solution (2.0 M) to benzazepine/THF solution was used. 1 mmol (0.5 mL) of LDA was
added after using enough LDA to first turn the content green (presumably creation of anion 8).
After 15 minutes, 1.0 mL of D2O was added to the flask and the solution became a dark
brown/red. The solution was partitioned between 15.0 mL of H2O and 15.0 mL of ether in a
separatory funnel. Drying over CaCl2 and removal of the solvents under reduced pressure gave
the product in the form of yellow viscous oil. Before and after chromatographic purification
(radial chromatography, 10% ethyl acetate/hexane) the product was analyzed by proton NMR
(CDCl3 solvent) to determine the extent of deuterium content, as judged by the diminution of the
CH2 signal at 3.4 ppm.
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Synthesis of methylated benzazepine 9B
Scheme 7
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General Method: The reaction occurred at -65°C using a dry ice 2-propanol slush bath. To a
flame-dried 3-neck reaction flask under nitrogen was added 1 mmol (295 mg) of 3H-1benzazepine 7. This was followed by 10.0 mL of THF. A 1:1 mole ratio of LDA solution (2.0
M) to benzazepine/THF solution was used. 1 mmol (0.5 mL) of LDA was added after using
enough LDA to first turn the content green (presumably creation of anion 8). After 30 minutes,
CH3I was added in ratio to the total amount of LDA used. The slush bath was removed and
immediately the solution color changed to a light green, followed by a light orange. At -33°C, it
became a dark orange and at -4°C, it was a deep red. The solution finally settled as a cloudy
yellow at 16°C.

After 10 minutes at room temperature, the solution was then partitioned

between 15.0 mL of H2O and 15.0 mL of ether in a separatory funnel. The organic layer was
dried over CaCl2 and the solvents were removed under reduced pressure to give the crude
product as yellow viscous oil. The product was purified by radial chromatography on silica gel
(1 mm plate, 1% ethyl acetate/hexane) and then later recrystallized from ethyl acetate/hexane to
give 192 mg 9B (30% yield) as yellow crystalline solid, melting point of 109-111°C.
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Synthesis of benzylated benzazepine 9C
Scheme 8
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General Method: The reaction occurred at -65°C using a dry ice 2-propanol slush bath. To a
flame-dried 3-neck reaction flask under nitrogen was added 2 mmol (590 mg) of 3H-1benzazepine 7. This was followed by 20.0 mL of THF. A 1:1 mole ratio of LDA solution (2.0
M) to benzazepine/THF solution was used. 2 mmol (1.0 mL) of LDA was added after using
enough LDA to first turn the content green (presumably creation of anion 8). After 1 hour,
benzyl bromide was added in ratio to the 2 mmol of LDA used. The slush bath was removed and
the solution remained a dark green until -16°C, when it changed to a red/brown color. At -10°C,
the solution was red/orange and at -7°C, it was a dark orange. Eventually, the solution became a
cloudy yellow at 20°C. After 10 minutes at room temperature, the solution was then partitioned
between 15.0 mL of H2O and 15.0 mL of ether in a separatory funnel. The organic layer was
dried over CaCl2 and the solvents were removed under reduced pressure to give the crude
product as yellow viscous oil. The crude product was purified by radial chromatography on
silica gel (4 mm plate, 2%, 5% ethyl acetate/hexane) to give two fractions and both were
recrystallized from ethyl acetate/hexane. Vacuum filtration separated each fraction into crystals
and filtrates.

Further radial chromatography (1 mm plate, 50% benzene/hexane) and

recrystallization were performed on the fraction 2 filtrate. A second recrystallization purified the
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fraction 1 filtrate. Isolated were 151 mg 1-benzylated isomer 21 (21% yield) as yellow solid, 40
mg less-polar 3- or 5-benzylated isomer 9C or 20 as a yellow solid (9% yield), 187 mg morepolar 3- or 5-benzylated isomer 9C or 20 as a yellow solid (43% yield), and 135 mg of 3H-1benzazepine starting material 7 as a yellow solid (23% recovery).

Synthesis of α-hydroxy alcohol benzazepine 9D
Scheme 9

N

7

Ph

N

H LDA
H
Ph

Ph
H

8

Ph

N

Anisaldehyde

9D

Ph

OH
H

H
Ph

OCH3

General Method: The reaction occurred at -65°C using a dry ice 2-propanol slush bath. To a
flame-dried 3-neck reaction flask under nitrogen was added 2 mmol (590 mg) of 3H-1benzazepine 7. This was followed by 20.0 mL of THF. A 1:1 mole ratio of LDA solution (2.0
M) to benzazepine/THF solution was used. 2 mmol (1.0 mL) of LDA was added after using
enough LDA to first turn the content green (presumably creation of anion 8). After 1 hour, panisaldehyde was added in ratio to the 2 mmol of LDA used. Upon addition, the solution
changed color to brown. The slush bath was removed and the solution changed color again at 51°C to dark orange. An hour later, at 20°C, the solution was just orange. After 10 minutes at
room temperature, the solution was then partitioned between 15.0 mL of H2O and 15.0 mL of
ether in a separatory funnel. The organic layer was dried over CaCl2 and the solvents were
removed under reduced pressure to give the crude product as yellow viscous oil. The product
was purified by radial chromatography on silica gel (4 mm plate, 15% ethyl acetate/hexane) to
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give two isolated fractions of interest. The solvents in each fraction were removed under
reduced pressure and both were recrystallized from ethyl acetate/hexane. Fraction one oiled out
after recrystallization twice, and was again recrystallized in an attempt to isolate it. Fraction two
was separated into two NMR samples: sample one with methanol-d, DMSO-d6, and acetic acidd4 as solvents; and sample two with solely acetic acid-d4 as a solvent. Sample one was
recrystallized from ethyl acetate/hexane to give 6 mg of crystals. Sample two could not be
isolated. Purification of these samples continues.

Conclusion
The deprotonation and electrophilic addition to the benzazepine molecule provides a new
window of options for benzazepine synthesis.

Deuteration experiments were initially used

during attempts to optimize deprotonation conditions.

The anion could be generated at

temperatures as low as -65°C. A significant level of deuterium incorporation indicated the
presence of the anion 8. Then, the alkylating agents methyl iodide and benzyl bromide were
used to place either a methyl group or benzyl group on the benzazepine. In the case of methyl
iodide, methylation occurred cleanly at C3 as expected and yielded 9B. The greatest yield out of
all three trials with this electrophile was 30% of a yellow crystalline solid, melting point 109111°C. Additionally, the methyl group at C3 locked the molecule into one conformation and no
conformational change was occurring.

This was determined by running NMR analysis at

different temperatures, and observing no change in the spectrum. In the case of benzyl bromide,
benzylation occurred at both C3 and C5, plus an unknown compound was produced. We now
know that the unknown is most likely the 1-benzylated isomer, but X-ray analysis is being
performed to confirm this. Recrystallization was able to purify the 1-benzyl-1-benzazepine
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crystals, with a melting point between 131-133°C. The more polar benzylated isomer has also
been purified as a yellow crystalline solid with a melting point of 123-124°C, but the less polar
isomer has thus far only been obtained in an impure state.
The final electrophile, p-anisaldehyde, resulted in two isomers at C3 and C5 as well. An
initial separation of the crude product gave two different fractions. Fraction one is still being
recrystallized, but NMR shows the presence of either 3- or 5-methoxy-benzyl alcohol. Fraction
two was split into two NMR samples. Sample one was eventually recrystallized and NMR
analysis of the crystals showed comparable peaks to fraction one, thus it is believed to be the
other isomer of 3- or 5-methoxy-benzyl alcohol. Sample two could not be isolated because there
was not enough product to analyze.
The ability to add different alkyl groups to the molecule allows for versatility in
producing 1-benzazepine derivatives. Future studies with other electrophiles will provide further
insight on this. This will lead to the eventual preparation of analogues of the CCR5 antagonist.
Additionally, the fact that substituting a hydrogen atom with a methyl group caused the
conformation of the molecule to lock into one position is an interesting find because this was not
the case for the unsubstituted 3H-1-benzazepine. Further studies of how other groups affect the
conformation of the molecule will provide a better understanding of this. The study of a
molecule’s conformation is important because it can affect its reactivity and pharmacological
activity.

25
Acknowledgements
I would like to thank my mentor, Dr. Keith Ramig, for allowing me to work with him on
this project and advising me throughout it. In addition, I want to thank Dr. Edyta Greer for her
supporting advice.

I also want to acknowledge Dr. David Szalda of Baruch College for

providing me with the supplemental X-ray analysis, Dr. Gopal Subramaniam of Queens College
for recording the high-resolution NMR spectra, and my colleagues Mr. Eric Gu and Mr. Nathan
Dvorkin who assisted me with the laboratory work.

26
References:
1. Centers for Disease Control and Prevention. “Basic Information about HIV and AIDS”
2010, Retrieved from http://www.cdc.gov/hiv/topics/basic/index.htm/
2. World

Health

Organization.

“HIV/AIDS”

2011,

Retrieved

from

http://www.who.int/topics/hiv_aids/en/
3. Lance Armstrong Foundation.

“HIV Treatment – HAART” 2009, Retrieved from

http://www.livestrong.com/article/14120-hiv-treatment-haart/
4. Stowell, D. “The Molecules of HIV” 2006, Retrieved from http://www.mcld.co.uk/hiv/
5. Carrington, M.; Dean, M.; Martin, M.P.; O’Brien, S.J. “Genetics of HIV-1 Infection:
Chemokine Receptor Ccr5 Polymorphism and Its Consequences” Oxford Journals 1999,
1939-1945.
6. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi,
M.; Aramaki, Y.; Okonogi, K.; Ogawa, Y.; Meguro, K. “A Small-molecule, Nonpeptide
CCR5 Antagonist with Highly Potent and Selective Anti-HIV-1 Activity” Proc. Natl.
Acad. Sci. USA 1999, 96, 5698-5703.
7. Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto,
M.; Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. “Discovery of Novel, Potent and
Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and
Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety” J.
Med. Chem. 2000, 43, 2049-2063.
8. Seto, M.; Aramaki, Y.; Okawa, T.; Miyamoto, N.; Aikawa, K.; Kanzaki, N.; Shin-ichi,
N.; Iizawa, Y.; Baba, M.; Shiraishi, M. “Orally Active CCR5 Antagonists as Anti-HIV-1
Agents: Synthesis and Biological Activity of 1-Benzothiepine 1,1-Dioxide and 1-

27
Benzazepine Derivatives Containing a Tertiary Amine Moiety” Chem. Pharm. Bull.
2004, 52, 577-590.
9. Seto, M.; Miyamoto, N.; Aikawa, K.; Aramaki, Y.; Kanzaki, N.; Iizawa, Y.; Baba, M.;
Shiraishi, M. “Orally Active CCR5 Antagonists as Anti-HIV-1 Agents. Part 3: Synthesis
and Biological Activitie of 1-Benzazepine Derivatives Containing a Sulfoxide Moiety”
Bioorg. Med. Chem. 2005, 13, 363-386.
10. Ramig, K.; Greer, E. M.; Szalda, D. J.; Razi, R.; Mahir, F.; Pokeza, N.; Wong, W.;
Kaplan, B.; Lam, J.; Mannan, A.; Missak, C.; Mai, D.; Subramaniam, G.; Berkowitz, W.
F.; Prasad, P.; Karimi, S.; Lo, N. H.; Kudzma, L. V. “Experimental and Theoretical
Studies of a One-Flask Synthesis of 3H-1-Benzazepines from 2-Haloanilines and α,βUnsaturated Ketones” Eur. J. Org. Chem. 2010, 2362-2371.
11. Ramig, K.; Alli, S.; Cheng, M.; Leung, R.; Razi, R.; Washington, M.; Kudzma, L. V.
“Synthesis of 2,4-Diaryl-3H-1-benzazepines” Synlett 2007, 2868-2870.
12. Brooke, G. M.; Matthews, R. S. “Partially Fluorinated Heterocycles. Part 25[1]. The
Formation of Fused-Ring 3H-Azepine Derivatives: 6,7,8,9-Tetrafluoro-2,4-diphenyl-3H1-benzazepine and 6,7,8,9,10,11-Hexafluoro-2,4-diphenyl-3H-napth[2,1-b]azepine”

J.

Fuorine Chem. 1988, 40, 109-117.
13. Singh, V.; Batra, S. “Synthesis of 1H- and 3H-1-Benzazepines and Rearrangement of
Alkyl 1H-1-Benzazepines-2-carboxylates into Isoquinolines” Eur. J. Org. Chem. 2007,
2970-2976.
14. Kharraz, B.; Uriac, P.; Toupet, L.; Hurvois, J. P.; Moinet, C.; Tallec, A.
“Electrochemical Oxidation of 2,5-Dihydro-1H-1benzazepines: Synthesis of 5H-1Benzazepines” Tetrahedron 1995, 51, 9611-9624.

28
15. Kharraz, B.; Uriac, P.; Sinbandhit, S.; Toupet, L. “Oxidation of 2,3-Dihydro-1H-1benzazepines by Hydride Transfer to an Iminium Ion: Synthesis of 3H-1-Benzazepines”
Tetrahedron 1996, 52, 4423-4432.
16. Streef, J. W.; van der Plas, H. C. “Azepines. I: The Formation and Reactivity of the
Anion of 2-Dimethylamino-5-phenyl-3H-azepine” Tetrahedron Letters 1979, 2287-2290.

29
Appendix
Methylated benzazepine 9B
NMR Spectrum

30
High Resolution NMR Spectrum

31

32

33
Data Tables of the Crystal Structure
Table 1.

Crystal data and structure refinement for KR21111.

Identification code

kr21111

Empirical formula

C23 H19 N

Formula weight

309.39

Temperature

296(2) K

Wavelength

0.71073 A

Crystal system, space group

Orthorhombic,

Unit cell dimensions

a = 13.2591(4) A
b = 25.5247(7) A
c = 10.0154(3) A

Volume

3389.56(17) A^3

Z, Calculated density

8,

Absorption coefficient

0.070 mm^-1

F(000)

1312

Crystal size

0.50 x ?0.50 x 0.40 mm

Theta range for data collection

2.21 to 27.49 deg.

Limiting indices

-17<=h<=16, -33<=k<=33, -13<=l<=12

Reflections collected / unique

16219 / 3853 [R(int) = 0.0356]

Completeness to theta = 27.49

99.5 %

Absorption correction

None

Refinement method

Full-matrix least-squares on F^2

Data / restraints / parameters

3853 / 1 / 218

Goodness-of-fit on F^2

1.054

Final R indices [I>2sigma(I)]

R1 = 0.0361, wR2 = 0.0896

R indices (all data)

R1 = 0.0455, wR2 = 0.0946

Absolute structure parameter

0.00

Largest diff. peak and hole

0.127 and -0.126 e.A^-3

Aba2
alpha = 90 deg.
beta = 90 deg.
gamma = 90 deg.

1.213 Mg/m^3
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Table 2.

Atomic coordinates ( x 10^4) and equivalent isotropic

displacement parameters (A^2 x 10^3) for KR21111.
U(eq) is defined as one third of the trace of the orthogonalized
Uij tensor.
________________________________________________________________
x

y

z

U(eq)

________________________________________________________________
N(1)

9304(1)

8324(1)

969(1)

52(1)

C(2)

9278(1)

8731(1)

1711(2)

48(1)

C(3)

10204(1)

9053(1)

2085(2)

52(1)

C(4)

10830(1)

8717(1)

3014(2)

48(1)

C(5)

11212(1)

8258(1)

2591(2)

51(1)

C(6)

11059(1)

8010(1)

1303(2)

52(1)

C(7)

10181(1)

8078(1)

522(1)

52(1)

C(21)

8269(1)

8895(1)

2214(2)

51(1)

C(22)

7408(1)

8706(1)

1584(2)

68(1)

C(23)

6460(1)

8851(1)

2005(2)

85(1)

C(24)

6345(2)

9178(1)

3069(2)

84(1)

C(25)

7171(2)

9362(1)

3719(2)

82(1)

C(26)

8133(1)

9222(1)

3299(2)

65(1)

C(41)

11028(1)

8912(1)

4383(2)

49(1)

C(42)

11130(1)

8574(1)

5460(2)

58(1)

C(43)

11340(1)

8761(1)

6724(2)

68(1)

C(44)

11444(1)

9288(1)

6942(2)

71(1)

C(45)

11343(1)

9630(1)

5900(2)

73(1)

C(46)

11142(1)

9446(1)

4632(2)

65(1)

C(31)

10774(1)

9263(1)

868(2)

67(1)

C(13)

11811(1)

7674(1)

817(2)

62(1)

C(14)

11735(2)

7442(1)

-421(2)

68(1)

C(15)

10894(2)

7524(1)

-1199(2)

69(1)

C(16)

10115(1)

7824(1)

-718(2)

62(1)

________________________________________________________________
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Table 3.

Selected bond lengths [A] and angles [deg] for KR21111.

_____________________________________________________________
N(1)-C(2)

1.2776(18)

C(2)-C(21)

1.489(2)

N(1)-C(7)
C(2)-C(3)
C(3)-C(4)

1.3964(19)
1.5236(19)
1.5137(19)

C(3)-C(31)

1.532(2)

C(4)-C(41)

1.482(2)

C(4)-C(5)
C(5)-C(6)

C(6)-C(13)
C(6)-C(7)

C(7)-C(16)

C(13)-C(14)
C(14)-C(15)
C(15)-C(16)
C(2)-N(1)-C(7)

1.344(2)
1.451(2)
1.403(2)
1.413(2)
1.403(2)
1.377(3)
1.376(3)
1.374(2)
125.12(12)

N(1)-C(2)-C(3)

123.98(13)

C(5)-C(4)-C(3)

120.45(13)

C(13)-C(6)-C(7)

117.91(14)

C(7)-C(6)-C(5)

123.67(13)

N(1)-C(7)-C(6)

124.33(13)

C(14)-C(13)-C(6)

121.52(17)

C(4)-C(3)-C(2)

C(4)-C(5)-C(6)

C(13)-C(6)-C(5)

N(1)-C(7)-C(16)

C(16)-C(7)-C(6)

C(15)-C(14)-C(13)

C(16)-C(15)-C(14)

C(15)-C(16)-C(7)

106.70(10)

127.38(14)

118.40(14)

116.07(14)

119.02(14)

120.30(16)

119.64(17)

121.42(17)

_____________________________________________________________
Symmetry transformations used to generate equivalent atoms:
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Table 4. Bond lengths [A] and angles [deg] for KR21111.
_____________________________________________________________
N(1)-C(2)
N(1)-C(7)
C(2)-C(21)
C(2)-C(3)
C(3)-C(4)
C(3)-C(31)
C(3)-H(3)
C(4)-C(5)
C(4)-C(41)
C(5)-C(6)
C(5)-H(5)
C(6)-C(13)
C(6)-C(7)
C(7)-C(16)
C(21)-C(26)
C(21)-C(22)
C(22)-C(23)
C(22)-H(22)
C(23)-C(24)
C(23)-H(23)
C(24)-C(25)
C(24)-H(24)
C(25)-C(26)
C(25)-H(25)
C(26)-H(26)
C(41)-C(42)
C(41)-C(46)
C(42)-C(43)
C(42)-H(42)
C(43)-C(44)
C(43)-H(43)
C(44)-C(45)
C(44)-H(44)
C(45)-C(46)
C(45)-H(45)
C(46)-H(46)
C(31)-H(31A)
C(31)-H(31B)
C(31)-H(31C)
C(13)-C(14)
C(13)-H(13)
C(14)-C(15)
C(14)-H(14)
C(15)-C(16)
C(15)-H(15)
C(16)-H(16)
C(2)-N(1)-C(7)
N(1)-C(2)-C(21)
N(1)-C(2)-C(3)
C(21)-C(2)-C(3)

1.2776(18)
1.3964(19)
1.489(2)
1.5236(19)
1.5137(19)
1.532(2)
0.9800
1.344(2)
1.482(2)
1.451(2)
0.9300
1.403(2)
1.413(2)
1.403(2)
1.383(2)
1.390(2)
1.377(3)
0.9300
1.362(3)
0.9300
1.358(3)
0.9300
1.390(3)
0.9300
0.9300
1.387(2)
1.395(2)
1.381(2)
0.9300
1.370(3)
0.9300
1.367(3)
0.9300
1.380(3)
0.9300
0.9300
0.9600
0.9600
0.9600
1.377(3)
0.9300
1.376(3)
0.9300
1.374(2)
0.9300
0.9300
125.12(12)
116.65(12)
123.98(13)
119.37(12)
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C(4)-C(3)-C(2)
C(4)-C(3)-C(31)
C(2)-C(3)-C(31)
C(4)-C(3)-H(3)
C(2)-C(3)-H(3)
C(31)-C(3)-H(3)
C(5)-C(4)-C(41)
C(5)-C(4)-C(3)
C(41)-C(4)-C(3)
C(4)-C(5)-C(6)
C(4)-C(5)-H(5)
C(6)-C(5)-H(5)
C(13)-C(6)-C(7)
C(13)-C(6)-C(5)
C(7)-C(6)-C(5)
N(1)-C(7)-C(16)
N(1)-C(7)-C(6)
C(16)-C(7)-C(6)
C(26)-C(21)-C(22)
C(26)-C(21)-C(2)
C(22)-C(21)-C(2)
C(23)-C(22)-C(21)
C(23)-C(22)-H(22)
C(21)-C(22)-H(22)
C(24)-C(23)-C(22)
C(24)-C(23)-H(23)
C(22)-C(23)-H(23)
C(25)-C(24)-C(23)
C(25)-C(24)-H(24)
C(23)-C(24)-H(24)
C(24)-C(25)-C(26)
C(24)-C(25)-H(25)
C(26)-C(25)-H(25)
C(21)-C(26)-C(25)
C(21)-C(26)-H(26)
C(25)-C(26)-H(26)
C(42)-C(41)-C(46)
C(42)-C(41)-C(4)
C(46)-C(41)-C(4)
C(43)-C(42)-C(41)
C(43)-C(42)-H(42)
C(41)-C(42)-H(42)
C(44)-C(43)-C(42)
C(44)-C(43)-H(43)
C(42)-C(43)-H(43)
C(45)-C(44)-C(43)
C(45)-C(44)-H(44)
C(43)-C(44)-H(44)
C(44)-C(45)-C(46)
C(44)-C(45)-H(45)
C(46)-C(45)-H(45)
C(45)-C(46)-C(41)
C(45)-C(46)-H(46)
C(41)-C(46)-H(46)
C(3)-C(31)-H(31A)

106.70(10)
114.68(12)
113.05(12)
107.4
107.4
107.4
121.12(13)
120.45(13)
118.41(12)
127.38(14)
116.3
116.3
117.91(14)
118.40(14)
123.67(13)
116.07(14)
124.33(13)
119.02(14)
117.37(15)
123.47(14)
119.15(15)
121.20(18)
119.4
119.4
120.38(19)
119.8
119.8
119.83(19)
120.1
120.1
120.4(2)
119.8
119.8
120.78(17)
119.6
119.6
117.26(14)
121.86(12)
120.87(13)
121.19(15)
119.4
119.4
120.33(17)
119.8
119.8
119.73(17)
120.1
120.1
120.26(15)
119.9
119.9
121.22(16)
119.4
119.4
109.5
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C(3)-C(31)-H(31B)

109.5

H(31A)-C(31)-H(31B)

109.5

C(3)-C(31)-H(31C)

109.5

H(31A)-C(31)-H(31C)

109.5

H(31B)-C(31)-H(31C)

109.5

C(14)-C(13)-C(6)

121.52(17)

C(14)-C(13)-H(13)

119.2

C(6)-C(13)-H(13)

119.2

C(15)-C(14)-C(13)

120.30(16)

C(15)-C(14)-H(14)

119.8

C(13)-C(14)-H(14)

119.8

C(16)-C(15)-C(14)

119.64(17)

C(16)-C(15)-H(15)

120.2

C(14)-C(15)-H(15)

120.2

C(15)-C(16)-C(7)

121.42(17)

C(15)-C(16)-H(16)

119.3

C(7)-C(16)-H(16)

119.3

_____________________________________________________________

Symmetry transformations used to generate equivalent atoms:
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Table 5.

Anisotropic displacement parameters (A^2 x 10^3) for KR21111.

The anisotropic displacement factor exponent takes the form:
-2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]
_______________________________________________________________________
U11

U22

U33

U23

U13

U12

_______________________________________________________________________
N(1)

53(1)

47(1)

56(1)

1(1)

-7(1)

-5(1)

C(2)

49(1)

44(1)

50(1)

5(1)

-8(1)

-4(1)

C(3)

52(1)

43(1)

61(1)

3(1)

-10(1)

-3(1)

C(4)

43(1)

46(1)

54(1)

4(1)

-5(1)

-6(1)

C(5)

50(1)

49(1)

55(1)

6(1)

-4(1)

2(1)

C(6)

58(1)

41(1)

56(1)

4(1)

2(1)

-3(1)

C(7)

57(1)

41(1)

57(1)

2(1)

1(1)

-8(1)

C(21)

52(1)

47(1)

54(1)

11(1)

-3(1)

-2(1)

C(22)

55(1)

72(1)

76(1)

-1(1)

-1(1)

-12(1)

C(23)

52(1)

108(1)

96(2)

6(1)

0(1)

-14(1)

C(24)

58(1)

111(2)

83(1)

22(1)

17(1)

10(1)

C(25)

79(1)

97(1)

70(1)

-1(1)

8(1)

15(1)

C(26)

60(1)

74(1)

62(1)

-1(1)

-4(1)

4(1)

C(41)

41(1)

50(1)

56(1)

0(1)

-1(1)

-2(1)

C(42)

53(1)

62(1)

60(1)

5(1)

-3(1)

1(1)

C(43)

62(1)

85(1)

56(1)

11(1)

-1(1)

-1(1)

C(44)

62(1)

96(1)

54(1)

-14(1)

-1(1)

-3(1)

C(45)

84(1)

63(1)

72(1)

-13(1)

-7(1)

-5(1)

C(46)

77(1)

55(1)

61(1)

0(1)

-8(1)

-4(1)

C(31)

67(1)

60(1)

74(1)

19(1)

-12(1)

-17(1)

C(13)

65(1)

48(1)

71(1)

2(1)

4(1)

2(1)

C(14)

80(1)

49(1)

74(1)

-3(1)

17(1)

0(1)

C(15)

91(1)

55(1)

62(1)

-6(1)

9(1)

-12(1)

C(16)

73(1)

54(1)

60(1)

-4(1)

-2(1)

-13(1)

_______________________________________________________________________
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Table 6.

Hydrogen coordinates ( x 10^4) and isotropic

displacement parameters (A^2 x 10^3) for KR21111.

________________________________________________________________

x

y

z

U(eq)

________________________________________________________________

H(3)

9969

9356

2599

62

H(5)

11622

8080

3192

62

H(22)

7474

8478

866

81

H(23)

5894

8725

1559

102

H(24)

5703

9274

3350

101

H(25)

7092

9583

4450

98

H(26)

8693

9351

3753

78

H(42)

11054

8215

5328

70

H(43)

11411

8527

7431

81

H(44)

11582

9413

7795

85

H(45)

11409

9988

6047

88

H(46)

11081

9683

3931

77

H(31A)

11326

9478

1161

100

H(31B)

10325

9469

328

100

H(31C)

11029

8975

352

100

H(13)

12374

7606

1343

74

H(14)

12254

7230

-732

81

H(15)

10854

7376

-2047

83

H(16)

9532

7860

-1224

75

________________________________________________________________
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Table 7. Torsion angles [deg] for KR21111.
________________________________________________________________
C(7)-N(1)-C(2)-C(21)
C(7)-N(1)-C(2)-C(3)
N(1)-C(2)-C(3)-C(4)
C(21)-C(2)-C(3)-C(4)
N(1)-C(2)-C(3)-C(31)
C(21)-C(2)-C(3)-C(31)
C(2)-C(3)-C(4)-C(5)
C(31)-C(3)-C(4)-C(5)
C(2)-C(3)-C(4)-C(41)
C(31)-C(3)-C(4)-C(41)
C(41)-C(4)-C(5)-C(6)
C(3)-C(4)-C(5)-C(6)
C(4)-C(5)-C(6)-C(13)
C(4)-C(5)-C(6)-C(7)
C(2)-N(1)-C(7)-C(16)
C(2)-N(1)-C(7)-C(6)
C(13)-C(6)-C(7)-N(1)
C(5)-C(6)-C(7)-N(1)
C(13)-C(6)-C(7)-C(16)
C(5)-C(6)-C(7)-C(16)
N(1)-C(2)-C(21)-C(26)
C(3)-C(2)-C(21)-C(26)
N(1)-C(2)-C(21)-C(22)
C(3)-C(2)-C(21)-C(22)
C(26)-C(21)-C(22)-C(23)
C(2)-C(21)-C(22)-C(23)
C(21)-C(22)-C(23)-C(24)
C(22)-C(23)-C(24)-C(25)
C(23)-C(24)-C(25)-C(26)
C(22)-C(21)-C(26)-C(25)
C(2)-C(21)-C(26)-C(25)
C(24)-C(25)-C(26)-C(21)
C(5)-C(4)-C(41)-C(42)
C(3)-C(4)-C(41)-C(42)
C(5)-C(4)-C(41)-C(46)
C(3)-C(4)-C(41)-C(46)
C(46)-C(41)-C(42)-C(43)
C(4)-C(41)-C(42)-C(43)
C(41)-C(42)-C(43)-C(44)
C(42)-C(43)-C(44)-C(45)
C(43)-C(44)-C(45)-C(46)
C(44)-C(45)-C(46)-C(41)
C(42)-C(41)-C(46)-C(45)
C(4)-C(41)-C(46)-C(45)
C(7)-C(6)-C(13)-C(14)
C(5)-C(6)-C(13)-C(14)
C(6)-C(13)-C(14)-C(15)
C(13)-C(14)-C(15)-C(16)
C(14)-C(15)-C(16)-C(7)
N(1)-C(7)-C(16)-C(15)
C(6)-C(7)-C(16)-C(15)

-172.64(13)
8.0(2)
-69.45(18)
111.21(14)
57.52(18)
-121.82(14)
62.00(17)
-63.99(18)
-119.48(13)
114.53(14)
177.91(13)
-3.6(2)
152.80(15)
-28.8(2)
-149.86(14)
39.0(2)
168.55(13)
-9.9(2)
-2.33(19)
179.26(13)
161.01(14)
-19.6(2)
-18.1(2)
161.28(13)
1.6(2)
-179.22(17)
-1.1(3)
0.1(3)
0.5(3)
-1.1(2)
179.80(16)
0.1(3)
-33.7(2)
147.82(13)
145.00(15)
-33.5(2)
-0.4(2)
178.35(14)
0.6(3)
-0.3(3)
-0.3(3)
0.6(3)
-0.3(3)
-178.98(17)
4.2(2)
-177.27(14)
-2.1(2)
-2.1(2)
4.0(2)
-173.32(13)
-1.7(2)
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Benzylated benzazepine 9C/20
NMR Spectra

Benzylated benzazepine 21
NMR
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44
Benzylated benzazepine 21
NMR Spectrum
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High Resolution NMR Spectrum
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α-Hydroxy alcohol benzazepine 9D/22
NMR Spectra
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